Senator Tom Cotton Statement on the FDA’s Accelerated Approval of the Muscular Dystrophy Drug Sarepta

Washington, D.C.— Senator Tom Cotton (R-Arkansas) today released the following statement on the Federal Drug Administration’s (FDA) accelerated approval of the Muscular Dystrophy drug Sarepta:
“I’m pleased the FDA gave accelerated approval to Sarepta, an important drug used to treat a form of muscular dystrophy that affects boys. In Arkansas, there are at least 60 boys who suffer from muscular dystrophy and I know this decision will give hope to them and their families. I applaud the efforts of Dr. Janet Woodcock, the head of the FDA’s drug evaluation office, and rare disease advocates in Arkansas and across the country who worked tirelessly to ensure this approval happened. Through hard-work and determination, they overcame the bureaucracy that stood in the way of giving patients with terminal diseases an opportunity for treatment. For drugs treating rare diseases,  the FDA should streamline the approval process to balance safety against the risk of preventing patients from having a chance to live a more full life.”